Effect of hyaluronic acid amide derivative on equine synovial fluid viscoelasticity
Source abstract
Abstract
Abstract An amphiphilic hyaluronic acid (HA) derivative has been obtained by the amidation of the carboxylic group of the glucuronic acid. This derivative, HYADD4®‐G (HY4), is the hexadecylamide of 500–730 kDa hyaluronic acid, derived from Streptococcus equi at about 2% degree of substitution (2 mol hexadecylamine per 100 mol hexuronic acid). Its viscoelastic properties, at a concentration of 5 mg/mL in phosphate buffer saline, have been compared with those solutions of native HA, having the same molecular weight. Changes in the viscoelastic properties of equine synovial fluid (SF) when mixed with HY4 over a series of volume ratios—viz 1:2, 1:1, 3:1, and 7:1—have been evaluated. HY4 is able to associate into aqueous solution, and its rheological behavior is typical of a weak gel. Throughout the frequency range investigated (0.1–10 Hz), the elastic modulus G′ is higher than the viscous modulus G″, and both moduli are frequency independent, and G′ value is about two orders of magnitude higher than that of a comparable solution of native HA. The addition of HY4 to equine synovial fluid (SF) increased its viscoelasticity at all the SF:HY4 ratios tested. These results demonstrate that HY4 is able to integrate with SF, increasing the synovial fluid rheology, and could be an interesting new option in viscosupplement therapy of osteoarthritis, particularly considering its low degree of chemical modification from native HA. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res, 2010
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Veterinary Equine Medical Research · Proteoglycans and glycosaminoglycans research · Polysaccharides Composition and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. 10.1096/fasebj.6.7.156359210.1096/fasebj.6.7.1563592 ↗
2. 10.1016/S0008-6215(00)90058-210.1016/S0008-6215(00)90058-2 ↗
3. 10.1002/bip.1968.36006060310.1002/bip.1968.360060603 ↗
4. Viscosupplementation: A new concept in the treatment of osteoarthritis
5. Viscosupplementation for treatment of osteoarthritis: From initial discovery to current status and results
6. 10.1016/S0950-3579(97)80009-X10.1016/S0950-3579(97)80009-X ↗
7. Hyaluronan in inflammatory joint disease10.3109/17453679509157665 ↗
8. Altman D · 1992 · 313
9. 10.3233/BIR-1993-305-61210.3233/BIR-1993-305-612 ↗
10. 10.1021/cr941199z10.1021/cr941199z ↗
11. Viscosupplementation for the treatment of osteoarthritis of the knee
12. Viscosupplementation for osteoarthritis
13. Rheologic changes in the synovial fluid of patients with gonarthitis induced by intraarticular infiltration
14. Long term effects of intrarticular hyaluronan on synovial fluid in osteoarthritis of the knee
15. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial
16. 10.1001/archinte.162.3.29210.1001/archinte.162.3.292 ↗
17. 10.1002/jbm.a.3097210.1002/jbm.a.30972 ↗
18. 10.1053/sarh.2002.3372010.1053/sarh.2002.33720 ↗
19. 10.1016/S0149-2918(98)80052-010.1016/S0149-2918(98)80052-0 ↗
20. 10.1097/00003086-200402000-0002110.1097/00003086-200402000-00021 ↗
21. Comparison of the effects of hyaluronan and its chemically cross‐linked derivative (Hylan G‐F 20) in normal rabbit knee joints
22. 10.2106/JBJS.E.0113510.2106/JBJS.E.01135 ↗
23. Granulomatous foreign body reaction against hyaluronic acid: Report of a case after lip augumentation10.1097/00042728-200312000-00018 ↗
24. 10.1046/j.1524-4725.2001.00248.x10.1046/j.1524-4725.2001.00248.x ↗
25. BelliniD TopaiA. Amides of hyaluronic acid and the derivatives thereof and a process for their preparation. EP Patent 1095064 1999.
26. 10.1002/1097-4636(200101)54:1<102::AID-JBM12>3.0.CO;2-110.1002/1097-4636(200101)54:1<102::AID-JBM12>3.0.CO;2-1 ↗
27. Borzacchiello A · 2004 · 265
28. 10.1021/bm005579810.1021/bm0055798 ↗
29. 10.1081/MA-10010157810.1081/MA-100101578 ↗
30. 10.1098/rsif.2005.008610.1098/rsif.2005.0086 ↗
31. Prestwich G · 2004 · 475
32. 10.1016/0144-8617(94)00089-C10.1016/0144-8617(94)00089-C ↗
33. 10.1002/art.1142110.1002/art.11421 ↗
34. 10.1016/S0142-9612(02)00194-110.1016/S0142-9612(02)00194-1 ↗
35. 10.1016/S0737-0806(85)80102-710.1016/S0737-0806(85)80102-7 ↗
36. 10.1007/978-1-4757-2257-410.1007/978-1-4757-2257-4 ↗
37. 10.1097/00001721-199102000-0002610.1097/00001721-199102000-00026 ↗
38. 10.1016/S0736-0266(02)00050-510.1016/S0736-0266(02)00050-5 ↗
39. 10.1007/PL0000574210.1007/PL00005742 ↗
40. 10.1016/j.pain.2006.11.01210.1016/j.pain.2006.11.012 ↗
41. 10.1016/S0928-4680(03)00024-510.1016/S0928-4680(03)00024-5 ↗
42. 10.1007/BF0065991910.1007/BF00659919 ↗
43. 10.1007/BF0091658110.1007/BF00916581 ↗
44. Evidence supporting an increase presence of reactive oxygen species in the diseased equine joint
45. 10.1128/jb.169.6.2516-2522.198710.1128/jb.169.6.2516-2522.1987 ↗
46. 10.1016/j.ijbiomac.2004.12.00310.1016/j.ijbiomac.2004.12.003 ↗